Compare IOSP & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | BCRX |
|---|---|---|
| Founded | 1938 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 1998 | 1994 |
| Metric | IOSP | BCRX |
|---|---|---|
| Price | $74.04 | $7.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $124.00 | $19.00 |
| AVG Volume (30 Days) | 275.5K | ★ 4.1M |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,789,200,000.00 | $599,816,000.00 |
| Revenue This Year | N/A | $41.57 |
| Revenue Next Year | $5.06 | $6.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 45.38 |
| 52 Week Low | $70.10 | $6.00 |
| 52 Week High | $120.69 | $11.31 |
| Indicator | IOSP | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 68.87 |
| Support Level | $72.96 | $7.11 |
| Resistance Level | $75.75 | $7.23 |
| Average True Range (ATR) | 1.92 | 0.29 |
| MACD | 0.34 | 0.11 |
| Stochastic Oscillator | 66.96 | 83.96 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.